JBCPL has its presence in the International market for over two decades. Its operations span over 50 countries around the globe. The company exports drug intermediates, bulk drugs and formulations to USA, Europe, Africa, CIS countries, Middle East, and South East Asia. The company was quick to respond to the opportunity of a liberalized Russian economy by establishing its representative offices in Moscow in 1994 and Kiev in 1998.

This facilitated a smooth entry in the Russian/ Ukrainian market. Fulfilling needs in these markets helped create a 286 strong field force and 40 distributors / iImporters in Russia and CIS alone.

Similarly company opened representative offices in Vietnam, Uganda, Tanzania & Sudan. The company has gone global with its strong marketing tie-ups in SriLanka, Malaysia, Vietnam & Myanmar to promote its specialty formulations.

The company is geared to meet the challenges of WTO TRIPS compliant markets having a strong regulatory team, which supports the international Division and helps in formulation development, analytical testing, quality assurance and medical departments.


REGULATORY ACHIEVEMENTS:
Success comes through achievements. So is our regulatory team who are successful in filling dossiers in more than 50 countries around the globe.

    • NDDS patents granted in United States of America for controlled release formulations of Ranitidine    
      and Tropical dental formulation of Metronidazole and Chlorhexidine for Periodontal treatment.

    • Metronidazole - Approved by US FDA and Therapeutic Goods Administration (TGA), Australia.
   
    • US Patent for novel pharmaceutical formulation of Metronidazole for dental application.

    • Patents also granted in South Africa for controlled release formulations Ranitidine and Nifedipine
      30 mg extended release tablets.

    • Patent application submitted “Pharmaceutical composition for controlled drug delivery systems”       covering new NDDS formulations of Ciprofloxacin OD and Ofloxacin OD.

   • ANDA’s filled for Ciproflocaxin and Flucanozole.

With a formidable turnover of Rs. 432 crores in FY 2010 it is contributing to 64% to the company’s total turnover, thus JBCPL is truly an International Marketing Company.

Company’s continuous focus on Brand Building has reaped rich dividends, due to which many of our brands have attained leadership status in their respective markets.

With consistent and focused promotion, JBCPL has ensured substantial growth year after year which is evident from the sales graph shown belows ensured substantial growths year after year which is evident from the sales graph shown below

GLOBAL RECOGNITION
JBCPL’s overseas brand “Doktor Mom” (modern herbal remedies for cold and cough) has achieved iconic status in Russia/CIS. Brand has won the Trusted Brand Award of Readers Digest for 7 successive years from 2001 to 2007.

JBCPL’s other block buster Brand RINZA ( speciality ethical remedy for cold and flu ) has now grown into its largest sales Brand in Russia/CIS .

JBCPL’s other strong overseas brands:

• Metrogyl
• Nicardia
• Metrogyl Denta
• Fitovit
• Zecuf
• Rantac
• Dicloran Plus Gel

Metrogyl Denta Gel is recognized and approved by Dental Associations of Russia, Ukraine and Kazakhstan, and permitted to print the logo of respective country’s Dental Associations with the text “Approved By “ on the primary packs.

Similarly Dicloran Plus Gel enjoys the patronage of the Rheumatological Associations of Russia which permit us to print their logo with the text “ Approved By” on the primary packs.

We have some more awards/recognitions in Russia n Ukraine. We shud add the same here.